The Exchange has sought clarification from Lupin Limited with respect to recent news item captioned Pharma stocks slump as Trump shoots letters to 17 global drug majors seeking lower prices. The response from the Company is attached.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Midcap 150 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin clarified to NSE and BSE that it has not received any letter from the US Government regarding prescription drug pricing, contrary to a Moneycontrol news article. The company stated it is not aware of any undisclosed information that could explain recent trading movement and confirmed there is no material impact on the company. Lupin referenced the official White House fact sheet showing the letters were sent to European and American pharmaceutical companies, and Lupin's name does not appear on that list. The company noted the news article was not specific to Lupin and did not warrant a confirmation or denial.
This is a routine exchange-driven clarification to address a rumor in the media. For shareholders, it removes near-term uncertainty by confirming Lupin was not among the drugmakers targeted, though the broader sector overhang from US drug pricing pressure remains.